Actively Recruiting
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Led by Peking University · Updated on 2026-04-21
110
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.
CONDITIONS
Official Title
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients have received neoadjuvant therapy and radical resection (R0).
- Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma.
- Patients must be able to provide sufficient fresh tissue/biopsies or minimum 5-10 FFPE sections for NGS-WES analysis.
- Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point.
You will not qualify if you...
- Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery.
- Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery.
- Other cases considered unsuitable for inclusion by researchers.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
Z
Ziyu Li, MD.,PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here